Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER+/HER2−) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2− breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations, including challenging administration by intramuscular injection and poor bioavailability, resulting in suboptimal drug exposure; hence, several next-generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. In this study, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced antitumor effects compared with single-agent alone. ZN-c5 also demonstrated bone-protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2− breast cancers. Although encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.
Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia were monitored by InAlyzer system overtime after drug treatment. D. Micro-CT analysis of tibia microarchitecture after at the end of study (12 weeks of drug treatment). E & F. BMD measured by micro-CT in femur and tibia. G. The ratio of uterine wet weight to body weight post-mortem. Statistical significance was evaluated by 2-Way ANOVA, *P < 0.05 compared with sham vehicle. #P < 0.05, ##P < 0.01, compared with OVX-vehicle. Sham, surgery control; OVX, Bilateral ovariectomy
Supplementary Table S5 shows Cell proliferation IC50 and maximum inhibition (Emax) in parental and ERY537S (heterozygous) after different ER ligands treatment.
Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after treatment with 0.1nM E2, 100nM ZN-c5 or 100nM fulvestrant. C. Western blot analysis of ER and PR protein after different concentrations of ZN-c5 treatment for the indicated time in MCF7 ERY537S heterozygous cells. ER or PR protein change (%) relative to non-treatment control after correction by GAPDH. D. WHIM20 tumor bearing mice were dosed with ZN-c5 or fulvestrant at PR protein level in WHIM20 tumor samples harvested at the end of an efficacy study. ZN-c5 was dosed at 40mg/kg, fulvestrant was dosed at 5mg/dose. E. ER expression in WHIM20 tumors by immunohistochemistry (IHC) at the end of efficacy study